A team of scientists from the University of Birmingham (UK) has developed a type of eye drops with the potential to revolutionize the treatment of one of the leading causes of blindness among the elderly: Macular degeneration associated with age. A medical condition that could multiply in the future due to the gradual aging of the world population.
Age-related macular degeneration causes the patient to gradually lose his central vision, usually in both eyes. The current treatment of age-related macular degeneration is based on repeated injections into the eyes, every month for at least three years. This is a problem because, aside from being an unpleasant procedure for patients, injections can cause tearing and infections inside the eye as well as an increased risk of blindness.
Eye drops may be used for other eye diseases that require similar eye injections
The results of this research, therefore, could mean the end of painful injections to treat this increasingly common eye disorder.
Thus, scientists led by the biochemist Felicity de Cogan of the Institute of Inflammation and Aging of the University of Birmingham (UK) have invented a method to manage the drug initially injected as an eye drops. In fact, his experiments in the laboratory have obtained the same results as the drug injected directly into the eye.
The revolutionary drop of the eye drops uses a cell-penetrating peptide (CPP) to deliver the drug to the related part of the eye within minutes. "The CPP drug has the potential to have a significant impact on the treatment of age-related macular degeneration, revolutionizing drug delivery options," explains de Cogan.